The challenges of new drugs benefits and risks analysis: Lessons from the ximelagatran FDA Cardiovascular Advisory Committee

This publication has 13 references indexed in Scilit:

• The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process
  Circulation, 2005
• Ximelagatran—Promises and Concerns
  Published by American Medical Association (AMA) ,2005
• Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions
  JAMA, 2004
• Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
  The Lancet, 2003
• Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects
  European Journal of Clinical Pharmacology, 2003
• Troglitazone-induced liver failure: a case study
  The American Journal of Medicine, 2003
• Medical Monitoring for Pharmaceutical Injuries
  JAMA, 2003
• Scientific and Ethical Issues in Equivalence Trials
  JAMA, 2001
• Statistics Notes: Blinding in clinical trials and other studies
  BMJ, 2000
• When placebo controlled trials are essential and equivalence trials are inadequate
  BMJ, 1998